Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy ...
The SARIL-RA-MONARCH trial has shown that sarilumab has greater impact on many patient-reported outcomes (PROs) than adalimumab does. Patient-reported outcomes (PROs) have proved to be a vital tool in ...
Paris and Tarrytown, New York - May 21, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. announced today that a Phase 3 study of sarilumab, an investigational, fully-human IL6 receptor antibody, met ...
TARRYTOWN, N.Y. and PARIS, May 21, 2015 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results